SEC Form 4 · accession 0001562180-17-000692
Syndax Pharmaceuticals Inc · SNDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard P Shea
Officer — Chief Financial Officer
Period of report
Feb 13, 2017
Accepted (ET)
Feb 15, 2017 · 10:32 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001395937
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $10.20 | Feb 13, 2017 | A | 125,000 | A | — | Feb 13, 2027 | Common Stock | 125,000 | 125,000 | D |
Explanation of responses
- F1Twenty-five percent (25%) of the total number of shares underlying the option shall vest on February 13, 2018, and one forty-eighth (1/48th) of the total number of shares underlying the option shall vest monthly thereafter on the last day of each month, subject to the reporting person's continuous service on the relevant vesting dates.